Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheng Yuan

Showing results (1391-1400 of 1,446) with videos related to

Pageof 145
Sort By:
The New England Journal of Medicine|January 8, 2025
Xalnesiran with or without an Immunomodulator in Chronic Hepatitis BJinlin Hou, Wenhong Zhang, Qing Xie, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|November 2, 2024
Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for de novo liver complications in hepatitis CChun-Ming Hong, Tung-Hung Su, Shih-Jer Hsu, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2023
Myeloid cell influx into the colonic epithelium is associated with disease severity and non-response to anti-Tumor Necrosis Factor Therapy in patients with Ulcerative ColitisDivya Jha, Zainab Al-Taie, Azra Krek, et al.
Medrxiv : the Preprint Server for Health Sciences|December 16, 2024
Plasticity of Human Microglia and Brain Perivascular Macrophages in Aging and Alzheimer's DiseaseDonghoon Lee, James M Vicari, Christian Porras, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 16, 2019
Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 CountriesJin-Lin Hou, Wei Zhao, Changhyeong Lee, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 17, 2016
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patientsTung-Hung Su, Tsung-Hui Hu, Chi-Yi Chen, et al.
Gut|January 7, 2021
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairmentChen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Hepatology International|March 7, 2021
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in TaiwanChen-Hua Liu, Po-Yueh Chen, Jyh-Jou Chen, et al.
Scientific Reports|June 18, 2017
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C PatientsMei-Hsuan Lee, Chung-Feng Huang, Hsueh-Chou Lai, et al.
Clinical and Molecular Hepatology|July 13, 2021
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosisChen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Pageof 145

Showing results (1391-1400 of 1,446) with videos related to

Sort By:
Pageof 145
The New England Journal of Medicine|January 8, 2025
Xalnesiran with or without an Immunomodulator in Chronic Hepatitis BJinlin Hou, Wenhong Zhang, Qing Xie, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|November 2, 2024
Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for de novo liver complications in hepatitis CChun-Ming Hong, Tung-Hung Su, Shih-Jer Hsu, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2023
Myeloid cell influx into the colonic epithelium is associated with disease severity and non-response to anti-Tumor Necrosis Factor Therapy in patients with Ulcerative ColitisDivya Jha, Zainab Al-Taie, Azra Krek, et al.
Medrxiv : the Preprint Server for Health Sciences|December 16, 2024
Plasticity of Human Microglia and Brain Perivascular Macrophages in Aging and Alzheimer's DiseaseDonghoon Lee, James M Vicari, Christian Porras, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 16, 2019
Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 CountriesJin-Lin Hou, Wei Zhao, Changhyeong Lee, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 17, 2016
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patientsTung-Hung Su, Tsung-Hui Hu, Chi-Yi Chen, et al.
Gut|January 7, 2021
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairmentChen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Hepatology International|March 7, 2021
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in TaiwanChen-Hua Liu, Po-Yueh Chen, Jyh-Jou Chen, et al.
Scientific Reports|June 18, 2017
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C PatientsMei-Hsuan Lee, Chung-Feng Huang, Hsueh-Chou Lai, et al.
Clinical and Molecular Hepatology|July 13, 2021
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosisChen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Pageof 145